Filsuvez gel for moderate to severe epidermolysis bullosa simplex
Part of Genetic & congenital, Skin clinical trials.
This trial tests a gel called Filsuvez on skin blisters and sores caused by epidermolysis bullosa simplex (EBS), a condition where skin is very fragile. The gel may help wounds heal faster and reduce pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of epidermolysis bullosa simplex (EBS).
- You need to have active blisters or sores covering at least 3% of your body surface area, with at least half of those being fresh or open.
- You cannot use other topical treatments (like medicated creams or special dressings) on the areas being treated during the study.
- You must be in generally good health and free of other skin conditions that could interfere.
- If you are a woman who can have children, you must have a negative pregnancy test and use effective birth control.
- You must be willing to follow the study schedule and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicated cream called TolaSure on skin affected by epidermolysis bullosa simplex (EBS), a condition that causes fragile skin and blistering. The cream aims to reduce blistering and improve healing by targeting a faulty protein in the skin. It is for people with localized, intermediate, or severe EBS who are currently having active blistering.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This study tracks anyone with dystrophic or junctional epidermolysis bullosa who is using Filsuvez gel to see how often skin cancers appear. It is designed to understand the long-term safety of the treatment.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This trial tests a new medicine called SD-101 for children with epidermolysis bullosa (EB), a condition that causes fragile skin and blistering. It aims to see if SD-101 can help heal wounds and improve quality of life.
Hear when a new Epidermolysis Bullosa Simplex trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.